Medical Device lead generation that finds decision-makers.
BeReach reads the public signals medical device companies leave behind, like funding rounds, FDA clearances, product launches and hiring. It qualifies each company against your ICP, then helps you reach the right decision-maker with a warm, contextual message.
1,000+ teams4.9| # | Name | Conn | Signal |
|---|---|---|---|
| 1 |  Elena Petrova VP Regulatory Affairs · Cordell Medical | 2nd | Liked the post |
| 2 |  Brandon Cole Director of Quality · NovaStent | 2nd | Commented |
| 3 |  Yuki Tanabe Head of Clinical Affairs · Aerovance | 3rd | Commented |
| 4 | Marco Bianchi Founder · Lumo Diagnostics | 2nd | Reposted |
| 5 | Diana Popescu Ops Manager · Kestrel Surgical | 3rd | Liked the post |
Medical device signals
funding, clearances, launches, hiring
Typical acceptance rate
warm, contextual first touch
Typical reply rate
vs generic cold outreach
To a qualified list
any class, any stage
Your agent scans where these accounts actually show up: funding and launch data, reviews and traction, tech stacks, hiring posts, and the people behind them.
Every account is scored against your ideal profile on size, stage, traction and buying signals, so noise is filtered out before it ever reaches you.
For each qualified account, the agent finds the right decision-maker and helps you send a contextual message that references a real signal, not a generic template.
An FDA 510(k), De Novo or PMA clearance means a device is heading to market and the team is standing up commercial and quality operations. Reach them while budgets and priorities are forming.
Know exactly when a device company raises, who led it, and how much. A freshly funded team is actively buying tools, services and partners while the budget is fresh.
New devices and expanded indications signal a company in motion. Lead with a reason tied to what they just brought to market, not a cold pitch.
A manufacturer posting regulatory, quality or commercial roles is scaling toward launch and beyond. Track hiring to find teams in active growth mode.
BeReach reads the public web in real time, across funding data, FDA clearance registries, product announcements, job boards and public profiles, then cross-references them to surface qualified companies along with the actual decision-maker's name and how to reach them. It is live signal, not a quarterly database dump.
Legacy databases index enterprise firmographics and refresh slowly, so early device startups and niche manufacturers are under-covered or missing entirely. BeReach searches the real-time sources where device companies actually surface, like funding, FDA clearances, launches and hiring, so it finds accounts those databases do not have.
Yes. Every lead is built from public signals across the open web, including public regulatory registries, cross-referenced and verified. There is no scraping behind a login and no private database, and targeting is B2B, focused on business decision-makers.
Funding stage and recency, FDA clearance status and class, product launches and indications, headcount and hiring activity. You describe your ICP in plain language and the agent scores each company against it, so only the strong-fit ones reach you.
Yes, and that is the difference from a list tool. After the Finder surfaces companies and the Qualifier scores them, the Reacher helps you open a warm, multichannel conversation with the right person, referencing a real signal like a recent clearance or a new raise instead of a generic template.
Yes. Just describe what you want, like a device startup with a recent 510(k) clearance hiring a VP of Regulatory in the US, and the agent handles the combination of class, clearance, role and buying signals. No filters or boolean syntax to learn.
Usually under two minutes. Describe the companies you want, the agent scans the public sources, qualifies them against your ICP, and returns a list with named decision-makers ready to reach out to.
The all-in-one AI SDR was supposed to replace your sales team. By early 2026, most companies that tried it have gone back to hybrid models. Here's what AI agents actually do well for LinkedIn prospecting - and where the hype still outpaces reality.
Alexandre Sarfati
Companies doing LinkedIn ABM well generate $10+ in pipeline per dollar spent and 44% higher ROAS than Google. But most ABM on LinkedIn fails because teams treat it like targeted cold outreach. Here's what the data shows actually works.
Alexandre Sarfati
Belkins analyzed over 20 million LinkedIn outreach attempts across 13,000 accounts. Here's what the data says about cold versus warm approaches, which combinations work, and what most teams get wrong.
Alexandre Sarfati
Describe your ideal device account and let your agent find, qualify, and reach the decision-makers behind it.
Free credits inside · no credit card
Click a button and let your favorite AI weigh in.
